GILD
US EQUITY
Health Care
Biotechnology
CIK: 882095
Gilead Sciences (GILD) Quant Factor Diagnostic & Fair Value Model
Gilead Sciences (Ticker: GILD) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$156.04
-0.73%
Latest Close (2026-10-23)
Market Cap: $189.80B
P/E Ratio: -
Momentum Strength
3M / 12M
+19.55%
1M: +4.24%
12M: +28.47%
Quality (ROE)
Point-in-Time
-109.50%
Trailing Return on Equity
Technical Trend
RSI 14
66.1
SMA50: $148.84
SMA200: $138.87
Valuation Multiplier
Trailing
-
Pre-Profit / Negative TTM
📊
Valuation & Multi-Factor Diagnostic
Pre-Profit / Negative TTM
GILD has negative or near-zero trailing GAAP earnings over the trailing twelve months.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 4/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 882095 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-06 | - | -$10.50B | $6.12B | $-8.45 |
| 10-Q | 2025-12-31 | 2026-08-06 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-06 | - | $1.96B | $2.58B | $1.56 |
| 10-Q | 2026-03-31 | 2026-05-07 | - | $2.02B | $2.54B | $1.61 |
| 10-Q | 2025-03-31 | 2026-05-07 | - | $1.31B | $1.76B | $1.04 |
| 10-K | 2025-12-31 | 2026-02-24 | - | $8.51B | $10.02B | $6.78 |
| 10-K | 2024-12-31 | 2026-02-24 | - | $480.00M | $10.83B | $0.38 |
| 10-K | 2023-12-31 | 2026-02-24 | - | $5.67B | $8.01B | $4.50 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Gilead Sciences (GILD) valuation multiples, momentum factors, and point-in-time filing conventions.
How should GILD's current valuation multiple be interpreted? ↓
GILD trades at a trailing P/E of -x within the Health Care sector (pre-profit / negative ttm). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are GILD's key momentum and technical factor indicators? ↓
As of the latest close, GILD shows a 1-month return of +4.24%, 3-month return of +19.55%, and 12-month return of +28.47%, with a 14-day RSI of 66.1. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for GILD? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can GILD be incorporated into systematic factor models? ↓
GILD can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.